These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38442612)

  • 1. Small-molecule modulators of tumor immune microenvironment.
    Zhang J; Yu J; Liu M; Xie Z; Lei X; Yang X; Huang S; Deng X; Wang Z; Tang G
    Bioorg Chem; 2024 Apr; 145():107251. PubMed ID: 38442612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.
    Chen S; Song Z; Zhang A
    Curr Top Med Chem; 2019; 19(3):180-185. PubMed ID: 30854972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
    Chen T; Li Q; Liu Z; Chen Y; Feng F; Sun H
    Eur J Med Chem; 2019 Jan; 161():378-398. PubMed ID: 30384043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].
    Pan G; Fan Y
    Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):786-793. PubMed ID: 31874675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy.
    Jiao P; Geng Q; Jin P; Su G; Teng H; Dong J; Yan B
    Curr Pharm Des; 2018; 24(41):4911-4920. PubMed ID: 30417781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
    Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
    Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
    Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
    Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule Drugs in Immunotherapy.
    Hao X; Chen Z; Li H; Wei M; Zuo Z; Su Q
    Mini Rev Med Chem; 2023; 23(13):1341-1359. PubMed ID: 36200242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
    Wan JL; Wang B; Wu ML; Li J; Gong RM; Song LN; Zhang HS; Zhu GQ; Chen SP; Cai JL; Xing XX; Wang YD; Yang Y; Cai CZ; Huang R; Liu H; Dai Z
    Cancer Lett; 2022 Aug; 541():215750. PubMed ID: 35609735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.